BACKGROUND: The Dialysis Access Consortium (DAC) was developed to investigate interventions to improve hemodialysis vascular access outcomes. The autogenous arteriovenous fistula created by direct connection of native artery to vein is the recommended vascular access for hemodialysis. However, it fails frequently due to clotting after surgery. PURPOSE: The DAC Early AV Fistula Thrombosis Trial tests the hypothesis that clopidogrel can prevent early fistula failure and increase the number of fistulas that ultimately become usable for hemodialysis access. This is one of two initial and concurrent trials being performed by the DAC. The companion trial investigates pharmacologic approaches to prevent venous stenosis leading to AV graft failure. METHODS: This is a multicenter, randomized, double-blind, placebo-controlled trial that will enroll 1,284 patients over four years. Patients undergoing creation of a new native arteriovenous (AV) fistula are randomized to treatment with clopidogrel or placebo for six weeks following fistula creation surgery. The primary outcome is fistula patency at six weeks. The major secondary outcome is fistula suitability for dialysis. RESULTS: This paper examines key aspects of this study that have broad relevance to trial design including: 1) the selection of an intermediate event as the primary outcome, 2) timing of the intervention to balance efficacy and safety concerns, 3) ethical considerations arising from required modifications of concomitant drug therapy, and 4) choosing an efficacy or effectiveness evaluation of the intervention. CONCLUSIONS: This is the first, large, multicenter trial evaluating a pharmacologic approach to prevent early AV fistula failure and promote more usable fistulas for hemodialysis. The methodologic challenges identified and addressed during the development of this trial should help to inform the design of future vascular access trials, and are relevant to clinical trials addressing a wide range of questions.
RCT Entities:
BACKGROUND: The Dialysis Access Consortium (DAC) was developed to investigate interventions to improve hemodialysis vascular access outcomes. The autogenous arteriovenous fistula created by direct connection of native artery to vein is the recommended vascular access for hemodialysis. However, it fails frequently due to clotting after surgery. PURPOSE: The DAC Early AV Fistula Thrombosis Trial tests the hypothesis that clopidogrel can prevent early fistula failure and increase the number of fistulas that ultimately become usable for hemodialysis access. This is one of two initial and concurrent trials being performed by the DAC. The companion trial investigates pharmacologic approaches to prevent venous stenosis leading to AV graft failure. METHODS: This is a multicenter, randomized, double-blind, placebo-controlled trial that will enroll 1,284 patients over four years. Patients undergoing creation of a new native arteriovenous (AV) fistula are randomized to treatment with clopidogrel or placebo for six weeks following fistula creation surgery. The primary outcome is fistula patency at six weeks. The major secondary outcome is fistula suitability for dialysis. RESULTS: This paper examines key aspects of this study that have broad relevance to trial design including: 1) the selection of an intermediate event as the primary outcome, 2) timing of the intervention to balance efficacy and safety concerns, 3) ethical considerations arising from required modifications of concomitant drug therapy, and 4) choosing an efficacy or effectiveness evaluation of the intervention. CONCLUSIONS: This is the first, large, multicenter trial evaluating a pharmacologic approach to prevent early AV fistula failure and promote more usable fistulas for hemodialysis. The methodologic challenges identified and addressed during the development of this trial should help to inform the design of future vascular access trials, and are relevant to clinical trials addressing a wide range of questions.
Authors: Xiaoyong Tong; Xiuyun Hou; Christopher Wason; Tal Kopel; Richard A Cohen; Laura M Dember Journal: Am J Pathol Date: 2017-08-17 Impact factor: 4.307
Authors: Rasheeda K Hall; Evan R Myers; Sylvia E Rosas; Ann M O'Hare; Cathleen S Colón-Emeric Journal: Clin J Am Soc Nephrol Date: 2017-05-18 Impact factor: 8.237
Authors: Timmy Lee; Michele Mokrzycki; Louise Moist; Ivan Maya; Miguel Vazquez; Charmaine E Lok Journal: Semin Dial Date: 2011-09-09 Impact factor: 3.455
Authors: Laura M Dember; Gerald J Beck; Michael Allon; James A Delmez; Bradley S Dixon; Arthur Greenberg; Jonathan Himmelfarb; Miguel A Vazquez; Jennifer J Gassman; Tom Greene; Milena K Radeva; Gregory L Braden; T Alp Ikizler; Michael V Rocco; Ingemar J Davidson; James S Kaufman; Catherine M Meyers; John W Kusek; Harold I Feldman Journal: JAMA Date: 2008-05-14 Impact factor: 56.272
Authors: Christoph B Olivier; Vandana Sundaram; Glenn M Chertow; Sumana Shashidhar; Lori K McDonnell; Victoria Y Ding; Manisha Desai; Kenneth W Mahaffey; Matthew Mell Journal: J Vasc Access Date: 2019-11-27 Impact factor: 2.283
Authors: Vijaya B Kolachalama; Moshe Shashar; Faisal Alousi; Sowmya Shivanna; Keshab Rijal; Mostafa E Belghasem; Joshua Walker; Shinobu Matsuura; Gary H Chang; C Michael Gibson; Laura M Dember; Jean M Francis; Katya Ravid; Vipul C Chitalia Journal: J Am Soc Nephrol Date: 2018-01-17 Impact factor: 14.978